|

Sargramostim Clinical Trials

7 actively recruiting trials across 7 locations

Also known as: 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, GM-CSF, Granulocyte Macrophage Colony Stimulating Factor, Leukine, Prokine, Sagramostim, Sargramostatin, granulocyte-macrophage colony-stimulating factor, rhu GM-CFS

Birmingham, Alabama1 trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Hospital of Alabama

Phase 3

Sacramento, California1 trial

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

University of California Davis Comprehensive Cancer Center

Phase 1/2

Aurora, Colorado1 trial

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

University of Colorado Anschutz Medical Campus

Phase 2

Jacksonville, Florida1 trial

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Mayo Clinic in Florida

Phase 1/2

Atlanta, Georgia1 trial

GM-CSF With Post-Transplant Cyclophosphamide

Northside Hospital

Phase 2

New York, New York1 trial

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2

Columbus, Ohio1 trial

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Nationwide Children's Hospital

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.